Abstract
This article aims to give an up-to-date review of studies on the diagnosis and treatment of patients with bladder cancer (BCa). We emphasize that the assessment of treatment and prognosis using specific markers is a promising method. However, clinical data currently outpace the results of molecular testing. Patients with luminal BCa demonstrate worse response to pharmacotherapy than those with other BCa types. The implementation of new drugs such as avelumab, enfortumab, and new drug combinations into clinical practice raised hopes to improve treatment outcomes of patients with locally advanced and metastatic bladder cancer. The development of new pharmacotherapy and immunotherapy regimens will improve treatment outcomes. We describe the experience of some foreign countries with the treatment and outpatient follow-up of patients after radical cystectomy. The article also contains the guidelines by the European Association of Urology on the treatment of patients with urinary tract cancers during the COVID-19 pandemic.
Highlights
This article aims to give an up-to-date review of studies on the diagnosis and treatment of patients with bladder cancer (BCa)
We describe the experience of some foreign countries with the treatment and outpatient follow-up of patients after radical cystectomy
The article contains the guidelines by the European Association of Urology on the treatment of patients with urinary tract cancers during the COVID-19 pandemic
Summary
Пациенты без CIS, не включенные в группы низкого, высокого или очень высокого риска Patients without CIS who are not included in either the low, high or very high-risk groups
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
